Name (Synonyms) | Correlation | |
---|---|---|
drug785 | Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection Wiki | 1.00 |
drug784 | Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin inhalation Wiki | 1.00 |
drug787 | Standard therapy recommended by the Ministry of Health of the Russian Federation. Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D011665 | Pulmonary Valve Insufficiency NIH | 0.58 |
D000860 | Hypoxia NIH | 0.33 |
D012141 | Respiratory Tract Infections NIH | 0.26 |
D011014 | Pneumonia NIH | 0.08 |
D007239 | Infection NIH | 0.08 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The purpose of the study is to evaluate an effectiveness of the drug Dalargin for the prevention and treatment of severe pulmonary complications symptoms associated with severe and critical coronavirus infection cases (SARS COVID19, expanded as Severe acute respiratory syndrome Cоrona Virus Disease 2019 ). Test drug that will be administered to patients are: - Dalargin, solution for inhalation administration, - Dalargin, solution for intravenous and intramuscular administration.
Description: Estimated by Polymerase chain reaction (PCR)
Measure: The change of viral load in patients with SARS-COVID-19. Time: Upon patient inclusion in the study, after 96 hours and on the 10day;Description: Assessed through the entire patient participation in the study
Measure: The frequency of development of Acute Respiratory Distress Syndrome (ADRS) Time: up to 8 monthsDescription: The number of days a patient is hospitalized
Measure: Duration of hospitalization Time: through study completion, an average of 8 monthsDescription: Early mortality from all causes will be estimated
Measure: The frequency of early mortality Time: up to 30 daysDescription: Late mortality from all causes will be estimated
Measure: The frequency of late mortality Time: up to 90 daysDescription: Clinical status at the time of completion of participation in the study will be estimated based upon the following criteria: Death; Hospitalization is extended, on invasive mechanical ventilation of the lungs with extracorporeal membrane oxygenation; Hospitalization extended, on non-invasive ventilation; Hospitalization is extended, needs additional oxygen; Hospitalization is extended, additional oxygen is not required; Discharged.
Measure: Clinical status at the time of completion of participation in the study Time: through study completion, an average of 8 months